# Novo Nordisk (NVO) cash on hand: DKK 26.96B in 2025

URL: https://funkfolio.com/stock/NVO/cash

> Novo Nordisk (NVO) cash on hand was DKK 26.96B at the end of fiscal 2025, up 2.5% from fiscal 2024. Year-by-year chart and table.

---

## Novo Nordisk (NVO) cash on hand

**Cash · fiscal 2025:** DKK 26.96B at Dec 31, 2025

Novo Nordisk (NVO) held cash of DKK 26.96B at the end of fiscal 2025 (December 31, 2025). That is 2.5% higher than the DKK 26.31B of fiscal 2024. Figures as of 18 Nov 2026, 10:31 UTC, from Yahoo Finance.

### Key facts

- **Cash, fiscal 2025:** DKK 26.96B
- **Change on fiscal 2024:** +2.5%
- **Highest on record:** DKK 30.23B fiscal 2023
- **Lowest on record:** DKK 23.57B fiscal 2022
- **Fiscal years on record:** 4 2022–2025

Figures as of 18 Nov 2026, 10:31 UTC. Statements from Yahoo Finance. Amounts are in DKK. Figures, not advice.

### Novo Nordisk cash on hand, in more detail

Across the 4 fiscal years on record (2022–2025), the highest was DKK 30.23B in fiscal 2023 and the lowest DKK 23.57B in fiscal 2022.

### Cash by fiscal year

### Novo Nordisk cash on hand, year by year

Novo Nordisk (NVO) cash on hand by fiscal year

| Fiscal year | Cash | Change | Year ended |
| --- | --- | --- | --- |
| 2025 | DKK 26.96B | 2.5% up | Dec 31, 2025 |
| 2024 | DKK 26.31B | 13.0% down | Dec 31, 2024 |
| 2023 | DKK 30.23B | 28.2% up | Dec 31, 2023 |
| 2022 | DKK 23.57B | — | Dec 31, 2022 |

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

### How it is calculated

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone.

### How to read it

Cash is the cushion that pays for bad years, buybacks and acquisitions; compare it with total debt to see whether the company is a net borrower.

### Cash at health care companies of similar size

Cash of Novo Nordisk and comparable companies

| Company | Cash | Fiscal year |
| --- | --- | --- |
| [Gilead Sciences GILD](https://funkfolio.com/stock/GILD/cash) | $9.61B | 2025 |
| [Abbott Laboratories ABT](https://funkfolio.com/stock/ABT/cash) | $8.94B | 2025 |
| Novo Nordisk NVO | DKK 26.96B | 2025 |
| [Pfizer PFE](https://funkfolio.com/stock/PFE/cash) | $13.60B | 2025 |
| [Danaher DHR](https://funkfolio.com/stock/DHR/cash) | $4.62B | 2025 |
| [Intuitive Surgical ISRG](https://funkfolio.com/stock/ISRG/cash) | $5.93B | 2025 |

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

### Novo Nordisk, figure by figure

- [Novo Nordisk market cap](https://funkfolio.com/stock/NVO/market-cap)
- [Novo Nordisk revenue](https://funkfolio.com/stock/NVO/revenue)
- [Novo Nordisk earnings](https://funkfolio.com/stock/NVO/earnings)
- [Novo Nordisk earnings per share (EPS)](https://funkfolio.com/stock/NVO/eps)
- [Novo Nordisk P/E ratio](https://funkfolio.com/stock/NVO/pe-ratio)
- [Novo Nordisk P/S ratio](https://funkfolio.com/stock/NVO/ps-ratio)
- [Novo Nordisk P/B ratio](https://funkfolio.com/stock/NVO/pb-ratio)
- [Novo Nordisk free cash flow](https://funkfolio.com/stock/NVO/free-cash-flow)
- [Novo Nordisk operating margin](https://funkfolio.com/stock/NVO/operating-margin)
- [Novo Nordisk dividend](https://funkfolio.com/stock/NVO/dividend)
- [Novo Nordisk shares outstanding](https://funkfolio.com/stock/NVO/shares-outstanding)
- [Novo Nordisk total debt](https://funkfolio.com/stock/NVO/total-debt)
- [Novo Nordisk total assets](https://funkfolio.com/stock/NVO/total-assets)
- [Novo Nordisk return on equity (ROE)](https://funkfolio.com/stock/NVO/roe)
- [Novo Nordisk return on invested capital (ROIC)](https://funkfolio.com/stock/NVO/roic)

[Novo Nordisk (NVO) overview: price, valuation and scorecard](https://funkfolio.com/stock/NVO) [All health care companies by market value](https://funkfolio.com/companies/sector/health-care)

### Novo Nordisk cash on hand: questions and answers

**How much cash does Novo Nordisk have?**

Novo Nordisk (NVO) held cash of DKK 26.96B at the end of fiscal 2025 (December 31, 2025). That is 2.5% higher than the DKK 26.31B of fiscal 2024.

**What are the highest and lowest cash figures on record for Novo Nordisk?**

Across the 4 fiscal years on record (2022–2025), the highest was DKK 30.23B in fiscal 2023 and the lowest DKK 23.57B in fiscal 2022.

**How is Novo Nordisk's cash calculated?**

Cash is the cash, cash equivalents and short-term investments on the balance sheet at the fiscal year-end, shown for the fiscal years the market data feed covers because the older SEC record counts cash and equivalents alone. For Novo Nordisk it is on record here for 4 fiscal years, 2022 to 2025.

Fiscal years are named for the calendar year they end in.

### Learn: cash on hand

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Market cap vs enterprise value: what is the difference?](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

  Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.

### Cite this page

Funkfolio, “Novo Nordisk (NVO) cash on hand”, data as of 18 November 2026. https://funkfolio.com/stock/NVO/cash

Underlying data: Yahoo Finance.
